IDEXX Laboratories, Inc. (IDXX) Insider Sells $503,750.00 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Giovani Twigge sold 2,015 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $250.00, for a total value of $503,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Giovani Twigge also recently made the following trade(s):

  • On Thursday, February 28th, Giovani Twigge sold 1,500 shares of IDEXX Laboratories stock. The shares were sold at an average price of $211.77, for a total value of $317,655.00.
  • On Wednesday, February 6th, Giovani Twigge sold 997 shares of IDEXX Laboratories stock. The stock was sold at an average price of $209.08, for a total value of $208,452.76.

Shares of NASDAQ:IDXX traded up $0.07 during trading on Friday, reaching $249.77. 240,966 shares of the company’s stock traded hands, compared to its average volume of 505,889. IDEXX Laboratories, Inc. has a fifty-two week low of $176.11 and a fifty-two week high of $258.45. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81. The stock has a market capitalization of $21.49 billion, a PE ratio of 58.63 and a beta of 0.97.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, beating the Zacks’ consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The firm had revenue of $576.06 million for the quarter, compared to analysts’ expectations of $575.04 million. During the same period last year, the firm earned $1.01 EPS. The company’s quarterly revenue was up 7.1% on a year-over-year basis. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current fiscal year.

IDXX has been the topic of several analyst reports. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, April 3rd. BidaskClub raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, March 22nd. Canaccord Genuity cut their price target on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating on the stock in a research report on Tuesday, March 26th. Finally, Guggenheim initiated coverage on IDEXX Laboratories in a research report on Thursday, May 23rd. They set a “buy” rating and a $276.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $256.71.

Several large investors have recently bought and sold shares of the company. Pearl River Capital LLC purchased a new position in IDEXX Laboratories in the 4th quarter valued at about $28,000. Coastal Investment Advisors Inc. purchased a new position in IDEXX Laboratories in the 1st quarter valued at about $37,000. Monetary Management Group Inc. purchased a new position in IDEXX Laboratories in the 1st quarter valued at about $45,000. Cresset Asset Management LLC purchased a new position in IDEXX Laboratories in the 1st quarter valued at about $63,000. Finally, Anderson Fisher LLC purchased a new position in IDEXX Laboratories in the 1st quarter valued at about $70,000. Hedge funds and other institutional investors own 87.77% of the company’s stock.

WARNING: “IDEXX Laboratories, Inc. (IDXX) Insider Sells $503,750.00 in Stock” was first published by Rockland Register and is the property of of Rockland Register. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://rocklandregister.com/2019/05/31/giovani-twigge-sells-2015-shares-of-idexx-laboratories-inc-idxx-stock.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: What is a Futures Contract?

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.